Lynx1 Capital Management LP Protagonist Therapeutics, Inc Transaction History
Lynx1 Capital Management LP
- $270 Million
- Q1 2025
A detailed history of Lynx1 Capital Management LP transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Lynx1 Capital Management LP holds 733,014 shares of PTGX stock, worth $32.7 Million. This represents 13.11% of its overall portfolio holdings.
Number of Shares
733,014Holding current value
$32.7 Million% of portfolio
13.11%Shares
1 transactions
Others Institutions Holding PTGX
# of Institutions
299Shares Held
61.3MCall Options Held
1.01MPut Options Held
555K-
Farallon Capital Management LLC San Francisco, CA6.11MShares$272 Million1.7% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$257 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.72MShares$255 Million4.53% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.28MShares$191 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3MShares$134 Million5.07% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.19B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...